Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists

Latest Casdin Capital, LLC Stock Portfolio

$1.31Billion– No. of Holdings #38

Casdin Capital, LLC Performance:
2024 Q2: 1.19%YTD: 11.09%2023: -13.17%

Performance for 2024 Q2 is 1.19%, and YTD is 11.09%, and 2023 is -13.17%.

About Casdin Capital, LLC and 13F Hedge Fund Stock Holdings

Casdin Capital, LLC is a hedge fund based in NEW YORK, NY. On 31-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $2.7 Billions. In it's latest 13F Holdings report, Casdin Capital, LLC reported an equity portfolio of $1.3 Billions as of 30 Jun, 2024.

The top stock holdings of Casdin Capital, LLC are BLFS, RVMD, SRPT. The fund has invested 14.2% of it's portfolio in BIOLIFE SOLUTIONS INC and 13.1% of portfolio in REVOLUTION MEDICINES INC.

The fund managers got completely rid off ABCELLERA BIOLOGICS INC (ABCL) and SINGULAR GENOMICS SYSTEMS IN (OMIC) stocks. They significantly reduced their stock positions in ALNYLAM PHARMACEUTICALS INC (ALNY), MONTE ROSA THERAPEUTICS INC (GLUE) and STRUCTURE THERAPEUTICS INC. Casdin Capital, LLC opened new stock positions in CONTINEUM THERAPEUTICS INC, GUARDANT HEALTH INC (GH) and SINGULAR GENOMICS SYSTEMS IN (OMIC). The fund showed a lot of confidence in some stocks as they added substantially to KYVERNA THERAPEUTICS INC, ILLUMINA INC (ILMN) and CENTURY THERAPEUTICS INC (IPSC).
Casdin Capital, LLC Equity Portfolio Value
Last Reported on: 18 Oct, 2024

Casdin Capital, LLC Annual Return Estimates Vs S&P 500

Our best estimate is that Casdin Capital, LLC made a return of 1.19% in the last quarter. In trailing 12 months, it's portfolio return was -2.09%.

New Buys

Ticker$ Bought
contineum therapeutics inc5,224,290
guardant health inc2,888,000
grail inc1,229,580
singular genomics systems in372,890

New stocks bought by Casdin Capital, LLC

Additions to existing portfolio by Casdin Capital, LLC

Reductions

Ticker% Reduced
alnylam pharmaceuticals inc-52.51
monte rosa therapeutics inc-48.91
structure therapeutics inc-37.32
revolution medicines inc-21.55

Casdin Capital, LLC reduced stake in above stock

Sold off


Casdin Capital, LLC got rid off the above stocks

Sector Distribution

Casdin Capital, LLC has about 88.4% of it's holdings in Healthcare sector.

Sector%
Healthcare88.4
7
Others4.6

Market Cap. Distribution

Casdin Capital, LLC has about 22% of it's portfolio invested in the large-cap and mega-cap stocks.

Category%
SMALL-CAP40.2
MID-CAP29.4
LARGE-CAP22
UNALLOCATED4.6
MICRO-CAP3.8

Stocks belong to which Index?

About 61.2% of the stocks held by Casdin Capital, LLC either belong to S&P 500 or RUSSELL 2000 index.

Index%
RUSSELL 200057.4
Others38.8
S&P 5003.8
Top 5 Winners (%)%
OMIC
singular genomics systems in
2012.5 %
SMFR
genedx holdings corp
152.7 %
RNA
avidity biosciences inc
60.1 %
ALNY
alnylam pharmaceuticals inc
29.9 %
SRPT
sarepta therapeutics inc
22.1 %
Top 5 Winners ($)$
SMFR
genedx holdings corp
55.7 M
RVMD
revolution medicines inc
36.1 M
RNA
avidity biosciences inc
32.0 M
SRPT
sarepta therapeutics inc
30.6 M
BLFS
biolife solutions inc
25.1 M
Top 5 Losers (%)%
DNA
ginkgo bioworks holdings inc
-71.2 %
PACB
pacific biosciences calif in
-63.5 %
VERV
verve therapeutics inc
-63.3 %
ABSI
absci corporation
-45.8 %
TNYA
tenaya therapeutics inc
-40.7 %
Top 5 Losers ($)$
LAB
standard biotools inc
-59.7 M
VERV
verve therapeutics inc
-25.7 M
EXAS
exact sciences corp
-17.4 M
TNYA
tenaya therapeutics inc
-14.3 M
RLAY
relay therapeutics inc
-13.4 M

Casdin Capital, LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Casdin Capital, LLC

Casdin Capital, LLC has 38 stocks in it's portfolio. About 77% of the portfolio is in top 10 stocks. LAB proved to be the most loss making stock for the portfolio. SMFR was the most profitable stock for Casdin Capital, LLC last quarter.

Last Reported on: 18 Oct, 2024
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions